Latest Information Update: 17 Apr 2007
At a glance
- Originator XiMed Group
- Class Antiparasitics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pediculosis
Most Recent Events
- 17 Apr 2006 Discontinued - Phase-I for Pediculosis in United Kingdom (Topical)
- 17 Nov 2003 Ximed Group is now called Eden Research
- 08 Jan 2001 Phase-I clinical trials for Pediculosis in United Kingdom (Topical)